Scientific Reports · 2017 · 100 citations · 26 references
MedicineCancer BiologyOncologyGene ExpressionMolecular OncologyNeoplasiaAngiogenesis In CancerCancer Cell SignalingCancer TranscriptomicsOncogenic Signaling PathwaysPancreatic CancerSignal Transduction In CancerCancer Signaling PathwaysCyclooxygenase-2 PathwayEpidermal Growth Factor Receptor SignalingMapk SignalingMitogen-activated Protein Kinase CascadesP38 Mitogen-activated Protein Kinase SignalingPro-tumorigenic SignalingTumor Angiogenesis Signaling
Cyclooxygenase-2 (COX-2) was stated to be overexpression in various human malignancies associating with angiogenesis, metastasis and chemoresistence. Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease displaying many of these characteristics. A common abnormality of PDAC is overexpression of specificity protein-1 (Sp1), which was said to correlate with malignant phenotypes of human cancers. Using RNA-seq data from The Cancer Genome Atlas (TCGA), we found that Sp1 expression was positively correlated with that of COX-2 in PDAC, and that the inhibition or overexpression of Sp1 in PDAC cells leads to decreased or elevated COX-2 expression. Luciferase reporter gene and chromatin immunoprecipitation (ChIP) assays revealed that elevated transcription of COX-2 requires Sp1 binding to sequence positions around -245/-240 of COX-2 promoter. Activated epidermal growth factor receptor (EGFR) and downstream p38 mitogen-activated protein kinase (p38-MAPK) were also profoundly altered in PDAC. The inhibition of EGFR/p38-MAPK signaling resulted in reduced Sp1 activation, decreased COX-2 and vascular endothelial growth factor (VEGF) expression. Thus, Sp1 could transcriptionally activate COX-2 expression in a process relies on activated EGFR/p38-MAPK signaling. Finally, we found that the inhibition of COX-2 leads to decreased angiogenesis in a process dependent on VEGF, which link COX-2 to angiogenesis in PDAC.
26
Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Peter Y. Park, Teresa A. Goldin, John C. S. Chang et al. · Case Reports in Oncology · 2015 · 5.3K citations · Full text
Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations
Medicine, Oncology, Pharmacology +17